and to determine the performance characteristics of the test for Down's syndrome, trisomy 18 and neural tube defects (NTDs). Methods MSS results were matched to pregnancy outcome information from the Perinatal Data Collection Unit and Birth Defects Register, using automated probabilistic record linkage. For unmatched pregnancies, manual follow-up was carried out by contacting referring doctors and hospitals, resulting in a very high follow-up rate of 99.2% (18,989/19,143). Results The sensitivity of MSS for Down's syndrome was 85% (23/27-95%CI 72-99%) with a falsepositive rate (FPR) of 6.8% (risk threshold X1 in 250). While using a fixed 5% FPR, the sensitivity for Down's syndrome was slightly lower (78%). The sensitivity for trisomy 18 was 44% (4/9 -95% CI 12-77%) with a FPR of 0.5% (risk threshold of X1 in 200). 11 of the 15 (73 -95%CI 51-97%) cases of open NTDs were detected from screening, with a 1% FPR (risk threshold alpha-fetoprotein [AFP] X2.5 MoM). All cases of anencephaly had increased AFP levels. Conclusion Probabilistic record linkage and manual follow-up is an efficient method for ascertainment of pregnancy outcomes, with a higher follow-up rate than that reported in similar studies. MSS should remain an available option for all pregnant women in Victoria, with test characteristics comparable with other recent reports of the quadruple test.
INTRODUCTION
T he use of prenatal screening tests for the detection of birth defects has become widespread over recent years. 1 Currently, there are several screening tests available involving maternal serum and/or ultrasound, each with different test characteristics and differing in the gestational range at which they can be carried out. The maternal serum screening (MSS) quadruple test is offered between 14 and 20 weeks gestation at Genetic Health Services Victoria (Genetic Health). The quadruple test has been described as the test of choice for Down's syndrome screening in the second trimester, 2 and is also used to provide a risk estimate for trisomy 18 3 and neural tube defects (NTDs). 4 Eligibility for prenatal diagnosis (amniocentesis or chorion villus sampling [CVS]) in Victoria requires pregnant women to be categorized at 'increased risk' -either because they are of advanced maternal age (37 years and over) or have an increased risk result from a prenatal screening test. The uptake of second trimester MSS by Victorian women from July 1998 to June 2000 was approximately 16%. More recently, the collective uptake of serum screening, either second trimester MSS or first trimester combined screening (available since February 2000), has been steadily rising from around 24% in 2000 to 30% in 2001, 42% in 2002 and 52% in 2003. 5 National 'Best Practice' Guidelines for prenatal screening state that there is a need for accurate, up-to-date information about local prenatal screening services for health practitioners and pregnant women. 6 Regular, comprehensive auditing of prenatal screening programmes is necessary to provide this information for evidence-based practice, [7] [8] [9] while results can be used by service providers for improving the test performance. The aim of this study was to determine the test characteristics of MSS provided by Genetic Health Services Victoria for the detection of Down's syndrome (trisomy 21), trisomy 18 and open NTDs.
METHODS
This evaluation involved following up all MSS tests provided by Genetic Health between July 1998 and June 2000. Between July and September 1998, the analytes measured were alpha-fetoprotein (AFP), free beta-human chorionic gonadotrophin (beta-hCG), unconjugated oestriol (uE 3 ) , and free alpha human chorionic gonadotrophin (alpha-hCG). In October 1998, alpha-hCG was replaced by inhibin-A, as it had been shown to give a better sensitivity for Down's syndrome. 10, 11 To calculate risk estimates for Down's syndrome and trisomy 18, the likelihood ratio is calculated from the analyte levels, converted to multiples of the median (MoM) by using gestational age, and corrected for maternal weight using the method of Wald and Cuckle. 12 The final risk is a combination of the maternal age risk at estimated date of delivery and the likelihood ratio to give an estimate of 'term risk'. The 'increased risk' result is defined as X1 in 250 for Down's syndrome and X1 in 200 for trisomy 18. AFP MoM level alone is used to calculate the risk for NTDs at 15 weeks gestation and over, with X2.5 MoM considered 'increased risk'.
An automated probabilistic record linkage technique was used to link MSS results (MSS database) with the pregnancy outcome information (Perinatal database) to obtain complete data on pregnancy outcomes of all pregnant women screened. Three databases were used for record linkage: The completeness and accuracy of these data on births and birth defects has been assessed in a number of ways. Over 99.6% of all births in Victorian hospitals were reported to the PDCU in 1996. 13 The overall notification of birth defects has been shown to be 88%, but notifications of chromosomal abnormalities apparent at birth was 100%, as were notifications of major structural abnormalities including NTDs. 14 Although these studies did not validate the notifications of birth defects for pregnancies terminated before 20 weeks gestation, a separate study showed that 85% of early terminations for birth defects were notified to the Victorian BDR between 1995 and 1999. 15 Furthermore, the manual follow-up stage of this maternal serum screening evaluation helped to ensure the highest possible ascertainment of birth defects, as well as to determine information on miscarriages (which are not reported to either the Perinatal database or the BDR).
Probabilistic record linkage allows for matches of common identifying variables such as name, date of birth and postcode. It calculates agreement or disagreement weights for each variable used when matching for a pair of records, and the sum of these weights provides an overall score for the pair. 16 Variables such as baby's date of birth, estimated date of delivery and gestation were used to confirm whether the correct pregnancy had been matched, as some women had been pregnant multiple times during the study period. Screened pregnancies not matched to the Perinatal database were manually checked with the BDR for terminations at less than 20 weeks gestation.
For pregnancies that did not match with either the Perinatal database or the BDR, a written request for pregnancy outcome information was sent to the referring doctor or hospital. Pathology and cytogenetics reports were collected for confirmation of birth defects where available.
This manual follow-up was time consuming but was essential to achieve a very high ascertainment of pregnancy outcomes.
Permission for access to the Perinatal database and BDR was obtained from the Consultative Council on Obstetric and Paediatric Mortality and Morbidity at the Victorian Government Department of Human Services. Ethical approval was granted by the Department of Human Services and The University of Melbourne Human Research Ethics Committees, as required by the Health Records Act 2001 (Vic).
Data analysis was performed on coded data using SPSS (version 11). Only tests done during the inhibin-A period were included in the analysis for Down's syndrome and trisomy 18. Those screened by alpha-hCG (n ¼ 2409) were excluded from the aneuploidy analyses but included in the calculations for NTDs (where AFP is the only analyte measured). Only pregnancies screened at 15 weeks gestation and over were given a risk for NTDs, unless the AFP level was X2.5 MoM at 14 weeks. All other 14-week results were excluded from the analysis for NTDs (n ¼ 1717).
Sensitivity (detection rate), false-positive rate (FPR) and positive predictive value (PPV) were calculated for each condition. The statistical significance of differences in proportion was assessed using w 2 tests (including Fisher's exact test where expected cell frequencies were less than five). Comparisons between groups are presented as relative risks (RR) with 95% confidence intervals (CI).
RESULTS
Pregnancy outcome information was ascertained for 99.2% of all pregnancies screened during the study period (Table 1) . Information on pregnancy outcome was sought from health professionals for 2.4% of cases, and 1.6% of cases were ascertained from this method. Of these 1.6% of cases, three cases of Down's syndrome, three cases of trisomy 18, one case of spina bifida and 84 miscarriages were identified which were not ascertained from record linkage.
The women having MSS ranged in age from 14 to 51 years, with a mean age of 30.3 years, and 20.1% of women aged 35 years and over. This is comparable with the Victorian population of women who gave birth between 1999 and 2000, who had a mean age of 29.8 years, with 18.7% of women 35 years and over. 17 There was no statistically significant difference in the maternal age distribution between groups with known or unknown pregnancy outcomes (w 2 A total of 6.9% of women in the cohort received an increased risk result for Down's syndrome (screen positive rate), with 6.8% being FPRs. Women at increased risk were more likely to be aged 37 and older compared with women not at increased risk (RR ¼ 3.7, 95%CI ¼ 3.3-4.1, Po0.0001). About 21% of women aged 37 and older had an increased risk result compared with 6% of women aged less than 37. There was no statistically significant difference in the proportion of women who were categorized at increased risk between groups with known (7%) or unknown (9%) pregnancy outcomes (w 2 ¼ 0.9, P ¼ 0.3). There were 27 cases of Down's syndrome ascertained in our cohort and, based on recent maternal age risk data, 18 this expected number was 42 at 16 weeks and 33 at term.
The sensitivity of the test for Down's syndrome was 85% (23/27 -95%CI ¼ 72-99%) with a 6.8% (1122/16,580) FPR ( Table 2 ). Of the 27 cases of Down's syndrome, 10 were to women aged 37 years or older and nine of these had an increased risk result (90%) when compared with 14 out of 17 (82%) for women under 37 years. When the FPR was fixed at 5%, the sensitivity of the test for Down's syndrome was lower at 78% (21/27), with a higher PPV.
The sensitivity of the test for trisomy 18 was 44% (4/9 -95%CI ¼ 12-77%) with 0.5% FPR. Additionally, one of the five low-risk cases of trisomy 18 was categorized as at increased risk for Down's syndrome and one of the cases at increased risk for trisomy 18 was also at increased risk for Down's syndrome. Upon using a risk threshold of X1 in 100, the sensitivity for trisomy 18 remained constant; however, the FPR decreased to 0.2% and the PPV increased.
There were 18 cases of open NTDs during the study period. However, three of these pregnancies had been screened at 14 weeks gestation and were not included in the analysis. These cases all had spina bifida and their AFP MoMs were 0.76, 1.42 and 1.79, screened at 14 þ 5, 14 þ 1 and 14 þ 6 weeks, respectively. The overall sensitivity of AFP screening for NTDs was 73% (11/15 -95%CI ¼ 51-97%) ( Table 3 ). There were six cases of anencephaly and all had an AFP X2.5 MoM (range 3.85-17.60 MoM, gestation screened between 15 þ 0 and 21 þ 0 weeks). There were eight cases of spina bifida, four (50%) of which had an increased risk result (AFP MoM range 0.81-5.86, gestation screened between 15 þ 0 and 17 þ 2 weeks). Three of the four pregnancies with spina bifida that were at low risk were terminated, suggesting a subsequent detection of spina 
DISCUSSION
The probabilistic record linkage technique was an efficient way to evaluate the quadruple MSS test, given the number of screened pregnancies which were managed by many different doctors and pregnancy services throughout the State of Victoria. Contacting referring doctors and hospitals for pregnancy outcome information (where record linkage was unable to find a match) was time consuming. However, the importance of this process was demonstrated by identification of some fetuses with an aneuploidy or NTD that were not found on the BDR, particularly the pregnancies that ended before 20 weeks gestation, and also for those pregnancies that ended in miscarriage. There were only three cases of Down's syndrome, three cases of trisomy 18 and one case of NTD that were not on the BDR. At the time of this study, the PDCU were not routinely linking the BDR to the cytogenetics laboratories to identify pregnancies with a chromosomal abnormality diagnosed through CVS or amniocentesis which were subsequently terminated or miscarried, and this is the main reason for why we completed the manual follow-up. This routine linkage is now occurring annually.
The overall follow-up rate (99.2%) of all pregnancy outcomes using the record linkage and manual follow-up techniques has resulted in the generation of reliable performance figures of MSS at Genetic Health. Different methods of follow-up have been used elsewhere with lower follow-up, such as using pregnancy outcome information from a screening database (94.8% -triple test evaluation), 19 or the serum, urine and ultrasound screening study (SURUSS) study, that assessed first and second trimester screening, where 96% of pregnancies had a documented outcome after using a variety of follow-up methods. 20 There was a discrepancy between observed numbers of Down's syndrome in our cohort and expected numbers based on maternal age risk estimates. 18 However, it is highly unlikely that we would have missed this number due to our record linkage with the BDR as well as extensive manual follow-up, resulting in 99.2% of pregnancy outcomes ascertained. The most likely explanation for this discrepancy is that the prevalence of Down's syndrome in this MSS population was reduced due to opportunistic nuchal translucency screening. Nuchal translucency was introduced in Victoria in 1997, and uptake of this test peaked in 1998-99 (first trimester combined screening was not introduced until 2000). Anecdotal evidence suggests that it was not uncommon for women to have nuchal translucency screening in the first trimester, and for those with a low risk result to have second trimester MSS as well. However, women with increased risk results from nuchal translucency screening would have had prenatal diagnosis, resulting in a lower risk population entering the MSS programme. One of the problems with estimating risk in a diluted population is that there are no accurate age-related risks estimates available, 21 and published risk data will result in an over-estimation of expected numbers. In addition, as the prevalence of Down's syndrome is lower in this population, the positive predictive value will be lower than that in an undiluted risk population with the same maternal age distribution.
The quadruple test has demonstrated a high sensitivity for Down's syndrome (85%, with a 6.8% FPR), and it should remain an option available to all pregnant women in Victoria. This result is comparable to other populations: for example, Wald et al. reported a sensitivity of 81% with an FPR of 7% 2 and the Health Technology Assessment SURUSS report demonstrated similar findings of a 6.2% FPR for a sensitivity of 85%. 20 The FPRs in these populations are slightly higher than the often-quoted 5%. 22 Using a fixed 5% FPR (equivalent to a risk threshold X1 in180) would have lowered the sensitivity for Down's syndrome to 78%, but the results are comparable with those reported for other populations, including 75% 2 and 83%. 20 Offering MSS with either a 7% or 5% FPR gives a better sensitivity than using maternal age alone. If maternal age of 37 years and over had been the only screening filter for prenatal diagnostic testing in this population, the sensitivity for Down's syndrome would have been less than half that of the quadruple test. A higher sensitivity based on maternal age alone (51% with a 14% FPR) has been shown elsewhere; however, this was based on the 'standard' threshold of X35 years, and using this threshold in our population gave comparable results. 2 The sensitivity for trisomy 18 was slightly lower (44% with a 0.5% FPR) than that found in a recent evaluation of the triple test with a sensitivity of 50% and 0.2% FPR. 19 However, due to our high follow-up rate of 99.2%, and with three cases of trisomy 18 ascertained through contact with health professionals, it is possible that more cases were identified in our populations than in other evaluation studies where follow-up was not as high. For example, the follow-up rate of one study was 94.8%. 19 A study examining cases and controls to estimate the test characteristics of the triple test for trisomy 18 showed a higher sensitivity of 60% with a 0.2% FPR. 3 However, these studies select cases on the basis of a known pregnancy outcome matched with a control and are biased towards trisomy 18 cases that are detected because of congenital abnormalities. Thus, they may result in an over-estimate of the test characteristics than can actually be achieved in practice. 23 Some programs do not use specific algorithms for trisomy 18 and instead use the risk calculations for Down's syndrome to detect this condition. 24 However, only two out of the nine pregnancies with trisomy 18 were categorized as being at increased risk for Down's syndrome in our study, so this method is questionable in our population. While using a risk threshold of Z1 in 100, as demonstrated by Palomaki et al., the sensitivity was unchanged but the FPR was lower and equivalent to other populations. 3 As the prevalence of trisomy 18 is low, estimates of sensitivity are not as robust as for Down's syndrome. This study has demonstrated that the trisomy 18 algorithm needs to be monitored for this population and may need adjusting, once more data are examined. It may become apparent that a risk threshold of X1 in 100 could be used, decreasing the proportion of women being offered prenatal diagnosis with associated anxiety and risk to pregnancy. However, as women who had screening were not direct patients of the centralized Genetic Health MSS Laboratory, we do not know the proportion of women who were subsequently offered prenatal diagnosis, following an increased risk result.
................ The sensitivity for NTDs was similar to that found elsewhere (72%), 19 although that programme had a more conservative AFP threshold of Z2.2 MoM and an FPR of 2%. As found elsewhere, 4 the sensitivity for anencephaly was higher than that for open spina bifida. Using an AFP threshold of Z2.0 MoM improved the sensitivity by 20% but resulted in a three-fold increase to the FPR. As the sensitivity for anencephaly and encephalocele was already at 100% using a Z2.5 MoM threshold, it remained the same using the lower cut-off, but the sensitivity for open spina bifida improved from 50% to 88% -an increase of nearly 40%. Similar sensitivities for NTDs have been found using the Z2.0 MoM cut-off, including 94% for anencephaly and 81-92% for open spina bifida with a 3.4% FPR. 4 When generating clinical-care pathways for the management of elevated AFP levels, it is vital to remember that a detailed ultrasound at 18-20 weeks gestation provides the most information about NTDs for all pregnancies, and this is the recommended follow-up test for AFP of X2.5 MoM at Genetic Health. For pregnancies with AFP results between 2.0 and 2.5 MoMs, it is recommended that the 'routine' 18-20 weeks ultrasound should be considered with an added emphasis on excluding NTDs, although it is not known whether this always occurs.
The information provided by this evaluation is relevant to clinical obstetric practice as it is important to have reliable, accurate data for clinicians to use when counselling women about prenatal testing options. There has been increasing recognition of the social and clinical importance of informed choice when making decisions about prenatal testing, 25 and there is evidence that some women may be undergoing prenatal screening, particularly MSS, without fully understanding the test or the meaning of an increased risk result. [26] [27] [28] Provision of relevant, good-quality information for women to facilitate informed choice about prenatal testing is a challenge for all antenatal care providers. 25 Information on the test performance and any associated risks are not always available, 29 and studies have shown that clinicians involved in antenatal care may not be fully informed about prenatal tests. [30] [31] [32] It is important that health professionals are equipped to provide relevant information to women as it has been found that the majority of women prefer face-to-face discussions with a doctor or counsellor as their main source of information. 33 
CONCLUSIONS
Automated record linkage combined with manual follow-up is an effective technique for conducting research audits of prenatal screening programmes leading to extremely high ascertainment of pregnancy outcome information. This study has shown that the quadruple test at Genetic Health has a high sensitivity for Down's syndrome, which is similar to the quadruple test in other populations. Although the pregnancies included in this study were screened in 1998-2000, there is no reason to believe the test characteristics of MSS will have changed at Genetic Health; however, it is possible that the demographic characteristics of the population of women screened may have changed. There is a need for regular evaluation of prenatal screening programmes as they can allow for modifications to the risk calculations and thresholds used. The results from this study have provided accurate, local information for health professionals to use when counselling pregnant women about prenatal screening.
